Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eve Hanna

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Market Access & Health Policy|February 22, 2020
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countriesJesper Jørgensen, Eve Hanna, Panos Kefalas
Journal of Market Access & Health Policy|April 29, 2016
Advanced therapy medicinal products: current and future perspectivesEve Hanna, Cécile Rémuzat, Pascal Auquier, et al.
Journal of Market Access & Health Policy|March 8, 2017
Gene therapies development: slow progress and promising prospectEve Hanna, Cécile Rémuzat, Pascal Auquier, et al.
Journal of Market Access & Health Policy|August 30, 2016
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trialsEve Hanna, Cecile Rémuzat, Pascal Auquier, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 14, 2018
Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative AssessmentSzymon Jarosławski, Eve Hanna, Monique Dabbous, et al.
Health Policy (Amsterdam, Netherlands)|June 6, 2020
Regenerative medicine regulatory policies: A systematic review and international comparisonTingting Qiu, Eve Hanna, Monique Dabbous, et al.
Regenerative Medicine|January 19, 2022
Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic reviewTingting Qiu, Michał Pochopień, Eve Hanna, et al.
Health Policy (Amsterdam, Netherlands)|November 12, 2021
Variation in market access decisions for cell and gene therapies across the United States, Canada, and EuropeSean Tunis, Eve Hanna, Peter J Neumann, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Market Access & Health Policy|February 22, 2020
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countriesJesper Jørgensen, Eve Hanna, Panos Kefalas
Journal of Market Access & Health Policy|April 29, 2016
Advanced therapy medicinal products: current and future perspectivesEve Hanna, Cécile Rémuzat, Pascal Auquier, et al.
Journal of Market Access & Health Policy|March 8, 2017
Gene therapies development: slow progress and promising prospectEve Hanna, Cécile Rémuzat, Pascal Auquier, et al.
Journal of Market Access & Health Policy|August 30, 2016
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trialsEve Hanna, Cecile Rémuzat, Pascal Auquier, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 14, 2018
Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative AssessmentSzymon Jarosławski, Eve Hanna, Monique Dabbous, et al.
Health Policy (Amsterdam, Netherlands)|June 6, 2020
Regenerative medicine regulatory policies: A systematic review and international comparisonTingting Qiu, Eve Hanna, Monique Dabbous, et al.
Regenerative Medicine|January 19, 2022
Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic reviewTingting Qiu, Michał Pochopień, Eve Hanna, et al.
Health Policy (Amsterdam, Netherlands)|November 12, 2021
Variation in market access decisions for cell and gene therapies across the United States, Canada, and EuropeSean Tunis, Eve Hanna, Peter J Neumann, et al.
Pageof 1